BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ravaioli F, Conti F, Brillanti S, Andreone P, Mazzella G, Buonfiglioli F, Serio I, Verrucchi G, Bacchi Reggiani ML, Colli A, Marasco G, Colecchia A, Festi D. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Dig Liver Dis. 2018;50:573-579. [PMID: 29567413 DOI: 10.1016/j.dld.2018.02.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association 2020;119:1019-40. [DOI: 10.1016/j.jfma.2020.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
2 Serenari M, Ravaioli F, Cucchetti A, Kim S, Cescon M. Reply to: “Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma”. Journal of Hepatology 2020;73:1270-1. [DOI: 10.1016/j.jhep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676 [PMID: 34904036 DOI: 10.4254/wjh.v13.i11.1663] [Reference Citation Analysis]
4 Huang R, Rao H, Yang M, Gao Y, Wang J, Jin Q, Ma D, Wei L. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy. Dig Dis Sci 2020;65:1491-500. [PMID: 31654313 DOI: 10.1007/s10620-019-05886-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
5 You MW, Kim KW, Shim JJ, Pyo J. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis. J Gastroenterol Hepatol 2021;36:601-8. [PMID: 32875681 DOI: 10.1111/jgh.15243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
6 Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26(24): 3326-3343 [PMID: 32655261 DOI: 10.3748/wjg.v26.i24.3326] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
7 Dajti E, Marasco G, Ravaioli F, Alemanni LV, Rossini B, Colecchia L, Vestito A, Festi D, Colecchia A. The role of liver and spleen elastography in advanced chronic liver disease. Minerva Gastroenterol (Torino) 2021;67:151-63. [PMID: 34027932 DOI: 10.23736/S2724-5985.20.02793-2] [Reference Citation Analysis]
8 Liang KH, Lai MW, Lin YH, Chu YD, Lin CL, Lin WR, Huang YH, Wang TH, Chien RN, Hu TH, Yeh CT. Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients. BMC Gastroenterol 2021;21:177. [PMID: 33865328 DOI: 10.1186/s12876-021-01761-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. Transl Gastroenterol Hepatol 2018;3:47. [PMID: 30148232 DOI: 10.21037/tgh.2018.07.06] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
10 Ahumada A, Rayón L, Usón C, Bañares R, Alonso Lopez S. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J Gastroenterol 2021; 27(40): 6737-6749 [PMID: 34790004 DOI: 10.3748/wjg.v27.i40.6737] [Reference Citation Analysis]
11 Serenari M, Han K, Ravaioli F, Kim S, Cucchetti A, Han D, Odaldi F, Ravaioli M, Festi D, Pinna AD, Cescon M. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. Journal of Hepatology 2020;73:855-62. [DOI: 10.1016/j.jhep.2020.04.032] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
12 Pons M, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, Buti M, Augustin S, Forns X, Mínguez B, Genescà J. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol 2020;72:472-80. [PMID: 31629779 DOI: 10.1016/j.jhep.2019.10.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 16.7] [Reference Citation Analysis]
13 Federico P, Giunta EF, Pappalardo A, Tufo A, Marte G, Attademo L, Fabbrocini A, Petrillo A, Daniele B. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel) 2021;14:233. [PMID: 33800217 DOI: 10.3390/ph14030233] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Alonso López S, Manzano ML, Gea F, Gutiérrez ML, Ahumada AM, Devesa MJ, Olveira A, Polo BA, Márquez L, Fernández I, Cobo JCR, Rayón L, Riado D, Izquierdo S, Usón C, Real Y, Rincón D, Fernández-Rodríguez CM, Bañares R. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Hepatology 2020;72:1924-34. [PMID: 33022803 DOI: 10.1002/hep.31588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
15 Florea M, Serban T, Tirpe GR, Tirpe A, Lupsor-Platon M. Noninvasive Assessment of Hepatitis C Virus Infected Patients Using Vibration-Controlled Transient Elastography. J Clin Med 2021;10:2575. [PMID: 34200885 DOI: 10.3390/jcm10122575] [Reference Citation Analysis]
16 Dajti E, Marasco G, Ravaioli F, Colecchia L, Ferrarese A, Festi D, Colecchia A. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness. JHEP Rep 2021;3:100289. [PMID: 34095798 DOI: 10.1016/j.jhepr.2021.100289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Mendizabal M, Piñero F, Ridruejo E, Herz Wolff F, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Videla Zuain MG, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, de Araujo A, Varón A, Rubinstein F, Cheinquer H, Silva M. Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology 2020;18:2554-2563.e3. [DOI: 10.1016/j.cgh.2020.02.044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
18 Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodriguez-Tajes S, Genesca J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2021:S0168-8278(21)02234-0. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Reference Citation Analysis]
19 Andreone P, Di Marco V, Gaeta GB, Fagiuoli S, Vukotic R, Craxì A. Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. Dig Liver Dis 2019;51:915-21. [PMID: 31031174 DOI: 10.1016/j.dld.2019.03.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
20 Marasco G, Dajti E, Ravaioli F, Alemanni LV, Capuano F, Gjini K, Colecchia L, Puppini G, Cusumano C, Renzulli M, Golfieri R, Festi D, Colecchia A. Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients. Hepatol Int 2020;14:850-7. [PMID: 32557193 DOI: 10.1007/s12072-020-10062-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
21 Morisco F, Federico A, Marignani M, Cannavò M, Pontillo G, Guarino M, Dallio M, Begini P, Benigno RG, Lombardo FL, Stroffolini T. Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. Cancers (Basel) 2021;13:3810. [PMID: 34359711 DOI: 10.3390/cancers13153810] [Reference Citation Analysis]
22 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
23 Dajti E, Ravaioli F, Festi D, Colecchia A. Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk. Hepatobiliary Surg Nutr 2020;9:505-7. [PMID: 32832504 DOI: 10.21037/hbsn.2019.11.19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 D'Ambrosio R, Degasperi E, Lampertico P. Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. J Hepatocell Carcinoma 2021;8:713-39. [PMID: 34235108 DOI: 10.2147/JHC.S292139] [Reference Citation Analysis]
25 Wang JH, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Kaohsiung J Med Sci. 2019;35:708-714. [PMID: 31430035 DOI: 10.1002/kjm2.12114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Macek Jilkova Z, Saleem K, Afzal S, Decaens T. Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV. Livers 2021;1:313-21. [DOI: 10.3390/livers1040024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Piñero F, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, Anders M, Schinoni MI, Reggiardo V, Palazzo A, Videla M, Alonso C, Santos L, Varón A, Figueroa S, Vistarini C, Adrover R, Fernández N, Perez D, Tanno F, Hernández N, Sixto M, Borzi S, Bruno A, Cocozzella D, Soza A, Descalzi V, Estepo C, Zerega A, de Araujo A, Cheinquer H, Silva M; LALREAN. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver Int 2019;39:1033-43. [PMID: 30636361 DOI: 10.1111/liv.14041] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
28 Søholm J, Hansen JF, Mössner B, Røge BT, Lauersen A, Hansen JB, Weis N, Barfod TS, Lunding S, Øvrehus A, Mohey R, Thielsen P, Christensen PB. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs. PLoS One 2020;15:e0243725. [PMID: 33301499 DOI: 10.1371/journal.pone.0243725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Kuo YH, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus. Kaohsiung J Med Sci 2021. [PMID: 34687140 DOI: 10.1002/kjm2.12465] [Reference Citation Analysis]
30 Mandorfer M, Hernández-Gea V, García-Pagán JC, Reiberger T. Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. Semin Liver Dis 2020;40:240-55. [PMID: 32557480 DOI: 10.1055/s-0040-1708806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
31 Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107 [DOI: 10.3748/wjg.v28.i1.96] [Reference Citation Analysis]